FDA issues Complete Response Letter for AbbVie's Trenibote for glabellar lines

AbbVie's Biologics License Application for Trenibote (trenibotulinumtoxinE) has encountered a regulatory setback after the US FDA issued a Complete Response Letter, citing deficiencies in manufacturing processes rather than clinical data. The CRL, disclosed by AbbVie on April 23, 2026, delays what would have been the first approval of a botulinum toxin serotype E product for aesthetic use in the United States.

The neurotoxin biologics license application had been filed seeking approval for Trenibote in the treatment of moderate to severe glabellar lines in adults. AbbVie said the FDA did not request any additional clinical studies as part of its response, a distinction that narrows the scope of the resubmission to manufacturing-related documentation. The company said it expects to submit a thorough response in the coming months, though no revised target action date has been disclosed.

The clinical evidence package underpinning the BLA was drawn from two pivotal Phase III clinical studies evaluating Trenibote for moderate to severe glabellar lines, alongside a Phase III open-label safety study. Across the development program, data were generated from more than 2,100 patients treated with trenibotulinumtoxinE. AbbVie has not publicly disclosed the primary endpoints, responder rates, or detailed safety outcomes from these studies, and the FDA's CRL does not appear to reflect concerns about the clinical evidence on the basis of the company's characterisation of the letter.

The CRL places Trenibote in a holding pattern within a field that already includes six US FDA-approved serotype A neuromodulators for glabellar lines: onabotulinumtoxinA (Botox Cosmetic), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), daxibotulinumtoxinA-lanm (Daxxify, approved September 2022), and letibotulinumtoxinA-wlbg (Letybo, approved February 2024). All approved products are serotype A. Trenibote, as a serotype E botulinum toxin competitor, would occupy a distinct pharmacological class within the indication.

The serotype distinction carries clinical relevance. Botulinum toxin serotype E cleaves SNAP-25 at a different site than serotype A, and the kinetic profile differs substantially. AbbVie has described onset as early as eight hours after administration — the earliest assessment time point in its clinical program — and a duration of effect of approximately two to three weeks. That profile contrasts with standard serotype A products, which typically demonstrate onset over three to seven days and duration of three to four months. Daxxify, the longest-acting approved product in the class, achieves a median duration of approximately six months through a peptide stabilisation technology. Trenibote's shorter duration positions it differently, potentially addressing a patient population deterred by the multi-month commitment associated with existing neuromodulators.

The FDA manufacturing process concerns cited in the CRL do not, on the basis of available information, reflect questions about the product's mechanism, clinical profile, or the adequacy of the Phase III data. The agency's decision not to request new clinical studies suggests the evidentiary basis for efficacy and safety was not the source of the deficiency. Manufacturing-related CRLs in the biologics space typically require sponsors to provide additional data on production processes, quality controls, or facility inspections, and can be resolved through documentation and facility remediation without repeating clinical work.

---

Spot something wrong? Report an issue with this article